DaVita eyes acquisitions, share buy-backs with cash windfall

Flush with $4.9 billion in cash from the pending sale of its medical group and as much as $130 million in expected benefits from federal tax reform, DaVita Inc. CEO Kent Thiry said Tuesday that the company will look to repurchase shares, grow its kidney-care business and make “a limited number of investments” in other health-care companies. The comments came during a quarterly earnings call — the Denver-based kidney-care provider’s first since it announced the sale of its disappointing managed-care…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news